key: cord-0847325-vrl99nhr
authors: Garmendia, Onintza; Monasterio, Carmen; Guzmán, Jesús; Saura, Laura; Ruiz, Concepción; Salord, Neus; Negrín, Miguel Anguel; Sanchez, Carlos Izquierdo; Suarez-Giron, Monique; Montserrat, Josep M; Torres, Marta
title: TELEMEDICINE STRATEGY FOR CPAP TITRATION AND EARLY FOLLOW-UP FOR SLEEP APNEA DURING COVID-19 AND POST-PANDEMIC FUTURE
date: 2021-02-13
journal: Arch Bronconeumol
DOI: 10.1016/j.arbres.2021.01.028
sha: 2b30a87038809333cafa0f9822a2cb9ed94cfe9f
doc_id: 847325
cord_uid: vrl99nhr

nan

With the acute first wave of the COVID-19 pandemic over (1), the long waiting list for sleep tests for OSA management has been further increased (2, 3) . The new preventive health measures against Covid-19 imply that patients go to the health centers as little as possible, which is why it is necessary to implement and start up a telematic workflow with home studies to guarantee sleep tests (4) , especially CPAP titration (5) (6) (7) (8) . We aimed to test a new telematic workflow to deliver CPAP therapy to OSA patients and to evaluate it in terms of CPAP compliance, costs, residual events, symptoms and satisfaction of patients. The usual titration strategy has the following steps. The patient is scheduled to the daytime-hospital for information, and educational and practical training session with the device (45 minutes). Then, our CPAP equipment is delivered to him/her for home titration (to be returned the next day), the data is downloaded, and a fixed pressure is prescribed. If the registration is incorrect, the titration is repeated another day. Finally, the patient is scheduled by the service company providing CPAP equipment that informs again how the equipment works, selects a final mask for treatment, and give a short practical session of the CPAP use.

The new telematic titration strategy was developed at 3 university hospitals -Clínic to attend a CPAP educational as a practical session. CPAP devices were initially set to automatic CPAP mode (range: 6-12 cmH2O) and equipped with a modem for remote data transmission and titration (EncoreAnywhere platform). The titration procedure was as follows. After the first night with CPAP treatment at home and for the following 2-3 days, a sleep technician telematically analyzed the automatic titration data from the A-trial program in order to set a fixed CPAP pressure value that normalized breathing (AHI <15 without major leaks). Patients received a phone call if massive leaks occurred based on the device data for >15% of sleep time or if CPAP use was <3 h. If leak was moderate no action was performed. If central apneas appeared, CPAP pressure was fixed at 70% of the initial value suppressing obstructive events. If a final decision-making on CPAP pressure was not established until the end of the third day of therapy, it was considered as a re-titration. In addition, at the end of the first week all patients received a brief phone call from the nurse to identify and solve any possible complications with the treatment (nasal congestion and leaks among others). CPAP parameters could also be modified if needed.During the first month of treatment the sleep technician/nurse could call the patient to solve any possible problems. In addition, the patient could contact the Sleep Unit nurse at any time through email or voicemail to solve any problem. At the end of the first month with CPAP, the nurse performed a follow-up visit by phone or videoconference aimed to assess the main outcomes: CPAP compliance, residual events and symptoms such as snoring, restful sleep, witnessed apneas and Epworth sleepiness scale. The nurse could solve any possible problem. Patients also received a phone call from staff who was not involved in patient management to answer a satisfaction questionnaire (9 modified) about the titration procedure.

To analyse the usefulness of the telematic titration two procedures were considered: CPAP compliance and cost-effectiveness. Regarding compliance, two groups were analysed. Compliance of the telematic titration group (n: 77) was compared with a historical cohort of 193 OSA patients from the year 2019 who were prospectively recruited from the 3 hospitals mentioned. Descriptive statistics were used for basic features of study data. Categorical variables were compared between groups (telematic vs control) using the chi-square test, whereas continuous variables were compared using the t-test or the nonparametric Mann-Whitney U test. Propensity score (PS) (10,11) was used to obtain a 1:1 balance between patients in the telematic group (n=55) and control group (n=55). Linear regression analyses were also used to examine the associations between continuous clinical parameter AHI and telematic and control group. The Main results were: 1. Compliance. In full cohort, telematic group patients (n=77) were younger with a lower BMI and ESS than in control group patients (n=193) (p=0.035, p<0.001 and p=0.042, respectively). However, after PS matching, no significant differences were found in the baseline characteristics (Table 1) . CPAP compliance showed similar values in the two groups in both full and PS matching cohort (p=0.099 and p=0.071, respectively); similar results were obtained using linear regression models, even after adjustment for center, in both full (p=0.111 and padjusted=0.106) and PS matching cohort (p=0.155 and padjusted=0.201). In telematic group, there were statistically significant differences between all baseline symptoms scores and 30-day are related to the follow-up contacts and replacing masks and humidifiers. The costs of the first informative contact and the titration data analysis account for the 8% of the total costs. Bayesian cost-effectiveness analysis concluded that the telematics strategy was cheaper with a probability higher than 99.9% and more effective with a probability of 94.22%. Finally, the patients stated that they were satisfied with the new procedure, 95.8 % were satisfied with the initial part of the treatment, 98.6 % with the follow-up and the 95.6 % with the access to the professionals. Although 18% of subjects would prefer face-to-face visits, most of them (93%) agreed that they would use the telematic procedure again and considered it convenient in the pandemic context. Regarding to the residual events, the median was 3.7 (1.65-6.85). All the clinical symptoms improved significantly after the telematic CPAP treatment (p<0.001). Finally, 10 out of the 77 patients included in the study could not be titrated with the telematic procedure.

This new and simple telemedicine strategy proposed in the COVID-19 pandemic is adequate and cost-effective and could contribute to speed up the reduction of waiting lists, with patient satisfaction. We believe that a remote strategy for CPAP titration should be based on 1. the patients should always use their own CPAP 2. the device should be able to remotely transmit data of CPAP treatment and be able to remote change of parameters which may avoid repetitive appointments for re-titration and 3. a system to hear the patient observations. 

Spain REFERENCES 1. Berekaa MM. Insights into the COVID-19 pandemic: Origin, pathogenesis, diagnosis, and therapeutic interventions

A systematic review of COVID-19 and obstructive sleep apnoea

Sleep Laboratories Reopening and COVID-19: A European Perspective

Home sleep testing in the era of COVID-19: a community perspective

Impact of COVID-19 lockdown on adherence to continuous positive airway pressure (CPAP) by obstructive sleep apnoea patients

Home PAP devices in patients infected with COVID-19

PAP therapy increases the risk of transmission of COVID-19

Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebulizer treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections

Comprehensive management of obstructive sleep apnea by telemedicine: Clinical improvement and costa Virtual Sleep Unit. A randomized controlled trial

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

Variable selection for propensity score models

Bayesian cost-effectiveness analysis from clinical trial data

The authors wish to thank the collaboration of Carmen Leon and Prof. Ramon Farré (University of Barcelona).Dear Editor,